Biochemical Assays Presentation Small Molecule 
Covalent Modifiers
JULY 25, 2024
We have integrated structural and quantitative proteomics with biochemical assays to decipher the mode of action of covalent USP30 inhibition by a small molecule containing a cyanopyrrolidine reactive group, USP30-I-1.
Drug Target Review
JULY 12, 2023
Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). We are pleased that to date our lead product candidate has aligned DCI profiles as expected.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Strateos Blog: Drug Discovery
DECEMBER 13, 2021
We are excited to share that Strateos’ SVP of Strategy & Operations, Daniel Sipes, will be delivering a presentation entitled Accelerating Medicinal Chemistry Cycle Times Through Cloud-Accessible Smart Automated Labs at the upcoming 2022 Society for Laboratory Automation and Screening Conference & Exhibition between February 5-9th.
Drug Target Review
JANUARY 5, 2024
Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays. Among the 13 N. 7 Figure 2: Structural model of the chosen N.
Molecular Design
DECEMBER 6, 2023
Put another way, the narrow scope of the data used to train the PAINS filter model restricts the applicability domain of this model to prediction of frequent-hitter behavior in these six assays. These compounds are found ubiquitously throughout commercial and academic small molecule screening libraries. [
Expert insights. Personalized for you.
182 
Let's personalize your content